China’s Jiangsu Aidea eyes Hong Kong listing as gateway to US and European Aids markets
Jiangsu Aidea Pharmaceutical, which develops anti-HIV and Aids treatments, plans to tap Hong Kong’s initial public offering (IPO) market as it sets its sights on expansion into the US and…